ReviewUrology2021
Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.
Review in Urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate.Histopathology · 2026Guideline
- Article
- Quantitative digital pathology reveals morphological and molecular correlates of tumor aggressiveness in prostate cancer.International urology and nephrology · 2026Article
- Spatially resolving cancer: from cell states to therapy.Trends in cancer · 2026Review
- Hypoxia and cribriform growth in prostate cancer - establishing a link via MRI.BMC medical imaging · 2025Article
- Article
- Link between multiple human papillomavirus 16 and 18 infection and prostate cancer, and relevance of tumor characteristics.Molecular and clinical oncology · 2025Article
- Article
- Quantitative 3-T Multiparametric MRI Parameters as Predictors of Aggressive Prostate Cancer.Radiology. Imaging cancer · 2025Article
- GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer.Neoplasia (New York, N.Y.) · 2024Article
- Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer.BMC cancer · 2024Article
- Intermediate risk prostate tumors contain lethal subtypes.Frontiers in urology · 2024Article
- Article
- DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology.International journal of molecular sciences · 2023Review
- Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.European urology open science · 2023Article
- Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease.Nature communications · 2022Article
- Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.Cancers · 2022Review
- Current conundrums with cribriform prostate cancer.Histopathology · 2022Article
- Prostate Pathology: What is New in the 2022 WHO Classification of Urinary and Male Genital Tumors?Pathologica · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Intraductal cribriform (IDC) and invasive cribriform morphologies are associated with worse prostate cancer outcomes. Limited retrospective studies have associated IDC and cribriform morphology with germline mutations in DNA repair genes, particularly BRCA2. These findings, which prompted the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer and Genetic/Familial High- Risk Assessment to consider germline testing for individuals with IDC/cribriform histology, have been questioned in a recent prospective study. A deepened understanding of the molecular mechanisms driving disease aggressiveness in cribriform morphology is critical to provide more clarity in clinical decision making. This review summarizes the current understanding of IDC and cribriform prostate cancer, with an emphasis on clinical outcomes and molecular alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.